Cathie's Ark Logo
Adaptive Biotechnologies Corp Logo

Combined Holdings of Adaptive Biotechnologies (ADPT) - Updated Daily

Liquid Biopsy
Date
Direction
Shares
Fund Weight
Fund
January 6, 2023
BUY82.875k0.0341%ARKG
January 5, 2023
BUY6.287k0.0026%ARKG
January 3, 2023
BUY34.428k0.0141%ARKG
November 2, 2022
BUY235.319k0.0779%ARKG
October 28, 2022
BUY14.879k0.0048%ARKG

Key Statistics

⚖️Weighting🧢Market Cap
0.59%$1.21b
🏋️‍♀️Weight Rank Across All Funds🌏Country
31🇺🇸United States
💳ARK Estimated Cost Average🎫ARK Ownership Percent
$28.21 - ARKG
6.25%
Description
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptive Biotechnologies believes the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Its proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. We have three commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
Website
www.adaptivebiotech.com

Other ETFs That Hold ADPT

Ticker
NameWeight
ARKGARK Genomic Revolution ETF4.07%
IBBiShares Biotechnology ETF0.11%

Research Notes and Commentary for ADPT